Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Arthritis Research and Therapy

Volumn 13, Issue 3, 2011, Pages

  Ducourau, Emilie ^a,b   Mulleman, Denis ^a,b   Paintaud, Gilles ^a,b   Miow Lin, Delphine C ^a,b   Lauféron, Francine ^a,b   Ternant, David ^a,b   Watier, Hervé ^a,b   Goupille, Philippe ^a,b  

^a UNIVERSITÉ DE TOURS   (France)

^b UNIVERSITY HOSPITAL OF TOURS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG ANTIBODY; INFLIXIMAB; INFLIXIMAB ANTIBODY; METHOTREXATE; PREDNISONE; UNCLASSIFIED DRUG; ANTIBODY; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANGIONEUROTIC EDEMA; ANKYLOSING SPONDYLITIS; ARTICLE; CHILL; DRUG BLOOD LEVEL; DRUG ERUPTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HYPERTHERMIA; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; TACHYCARDIA; TREATMENT DURATION; BLOOD; DOSE RESPONSE; DRUG MONITORING; IMMUNOLOGY; KAPLAN MEIER METHOD; MIDDLE AGED; SPONDYLARTHRITIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPONDYLARTHRITIS; YOUNG ADULT;

EID: 79959573331     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3386     Document Type: Article

References (19)

1. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor α monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 1998, 41:1552-1563. 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W, 9751087.
2. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, Golder W, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Reddig J, Sieper J. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. Arthritis Rheum 2003, 48:2224-2233. 10.1002/art.11104, 12905476.
3. van der Heijde D, Dijkmans B, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J, . Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591. 10.1002/art.20852, 15692973, Ankylosing Spondylitis Study for the Evaluation of Recombinant Infliximab Therapy Study Group.
4. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor α inhibitor infliximab. Arthritis Rheum 2006, 54:3782-3789. 10.1002/art.22214, 17133559.
5. Wolbink GJ, Vis M, Lems W, Voskuyl AE, de Groot E, Nurmohamed MT, Stapel S, Tak PP, Aarden L, Dijkmans B. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715. 10.1002/art.21671, 16508927.
6. de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BA, Aarden LA, van der Horst-Bruinsma IE. Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 2007, 66:1252-1254. 10.1136/ard.2007.072397, 1955152, 17472991.
7. Krzysiek R, Breban M, Ravaud P, Prejean MV, Wijdenes J, Roy C, Henry YD, Barbey C, Trappe G, Dougados M, Emilie D, . French Ankylosing Spondylitis Infliximab Network Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 2009, 61:569-576. 10.1002/art.24275, 19405015, French Ankylosing Spondylitis Infliximab Network.
8. Fautrel B, Pham T, Mouterde G, Le Loët X, Goupille P, Guillemin F, Ravaud P, Cantagrel A, Dougados M, Puéchal X, Sibilia J, Soubrier M, Mariette X, Combe B, . Club Rhumatismes et Inflammation, Société Française de Rhumatologie Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with rheumatoid arthritis. Joint Bone Spine 2007, 74:627-637. 10.1016/j.jbspin.2007.10.001, 18037319, Club Rhumatismes et Inflammation, Société Française de Rhumatologie.
9. Pham T, Fautrel B, Dernis E, Goupille P, Guillemin F, Le Loët X, Ravaud P, Claudepierre P, Miceli-Richard C, de Bandt M, Breban M, Maillefert JF, Masson C, Saraux A, Schaeverbeke T, Wendling D, Mariette X, Combe B, . Club Rhumatismes et Inflammation (CRI/SFR) Recommendations of the French Society for Rheumatology regarding TNFα antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update. Joint Bone Spine 2007, 74:638-646. 10.1016/j.jbspin.2007.10.003, 18065252, Club Rhumatismes et Inflammation (CRI/SFR).
10. Ternant D, Mulleman D, Degenne D, Willot S, Guillaumin JM, Watier H, Goupille P, Paintaud G. An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab. Ther Drug Monit 2006, 28:169-174. 10.1097/01.ftd.0000189901.08684.4b, 16628126.
11. Van Assche G, Magdelaine-Beuzelin C, D'Haens G, Baert F, Noman M, Vermeire S, Ternant D, Watier H, Paintaud G, Rutgeerts P. Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology 2008, 134:1861-1868. 10.1053/j.gastro.2008.03.004, 18440315.
12. Mulleman D, Méric JC, Paintaud G, Ducourau E, Magdelaine-Beuzelin C, Valat JP, Goupille P, . Centre National de la Recherche Scientifique UMR 6239 GICC Infliximab concentration monitoring improves the control of disease activity in rheumatoid arthritis. Arthritis Res Ther 2009, 11:R178. 10.1186/ar2867, 3003525, 19939280, Centre National de la Recherche Scientifique UMR 6239 GICC.
13. The R Project for Statistical Computing. , http://www.R-project.org/
14. Xu Z, Seitz K, Fasanmade A, Ford J, Williamson P, Xu W, Davis HM, Zhou H. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008, 48:681-695. 10.1177/0091270008316886, 18401017.
15. Ternant D, Aubourg A, Magdelaine-Beuzelin C, Degenne D, Watier H, Picon L, Paintaud G. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008, 30:523-529.
16. Bartelds GM, Krieckaert CL, Nurmohamed MT, van Schouwenburg PA, Lems WF, Twisk JW, Dijkmans BA, Aarden L, Wolbink GJ. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468. 10.1001/jama.2011.406, 21486979.
17. Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, Euller-Ziegler L, Pham T, Solau-Gervais E, Chary-Valckenaere I, Perdriger A, Le Loët X, Wendling D, Fautrel B, Fournié B, Combe B, Gaudin P, Jousse S, Mariette X, Baleydier A, Trape G, Dougados M, . French Ankylosing Spondylitis Infliximab Network Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 2008, 58:88-97. 10.1002/art.23167, 18163509, French Ankylosing Spondylitis Infliximab Network.
18. Mulleman D, Chu Miow Lin D, Ducourau E, Emond P, Ternant D, Magdelaine-Beuzelin C, Valat JP, Paintaud G, Goupille P. Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritis. Ther Drug Monit 2010, 32:232-236.
19. Chu Miow Lin D, Mulleman D, Azzopardi N, Griffoul-Espitalier I, Valat JP, Paintaud G, Goupille P. Trough infliximab concentration may predict long-term maintenance of infliximab in ankylosing spondylitis. Scand J Rheumatol 2010, 39:97-98. 10.3109/03009740903177745, 20132079.